Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · May 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying early genetic screening to help identify serious genetic conditions in newborns. Researchers aim to create a program that will allow for early detection of hereditary illnesses, which can lead to better diagnosis and treatment options for affected infants. The trial is currently looking for participants, including newborns who are less than 100 days old and those who have experienced perinatal death after 20 weeks of pregnancy. Parents or guardians of these infants must provide consent for their child's participation.

If you choose to participate, you will be part of a program that collects genetic information to help understand and potentially treat critical illnesses in newborns. It's important to know that if you have concerns about sharing genetic data or if you don't have the necessary samples for testing, you may not be eligible for this study. Overall, this trial could play a crucial role in improving care for newborns with genetic conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Postnatal age less than 100 days;
• • Perinatal death after 20 weeks of gestation (more than 500 g)
• • Can be retained biological samples for genetic screening;
• • Biological parent or guardian's informed consent.
• Exclusion Criteria:
• • Reluctance of parents to use genetic sequencing data for subsequent research;
• • Parents under 18 years of age or incapacitated for decision-making;
• • subjects older than 100 days;
• • Perinatal death less than 20 weeks of gestation or weight less than 500 g;
• • Inherited metabolic diseases with chromosomal abnormalities;
• • Multiple pregnancies;
• • Lack of access to biological samples from which DNA can be extracted;
• • Failure to sign informed consent.